Human African trypanosomiasis in areas without surveillance.
about
Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sicknessEscaping Deleterious Immune Response in Their Hosts: Lessons from TrypanosomatidsNECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sicknessSafety, pharmacokinetic, and efficacy studies of oral DB868 in a first stage vervet monkey model of human African trypanosomiasisHuman African Trypanosomiasis in the Democratic Republic of the Congo: A Looming Emergency?Population vulnerability and disability in Kenya's tsetse fly habitatsThe human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forwardPrevalence of human African trypanosomiasis in the Democratic Republic of the CongoChallenges of controlling sleeping sickness in areas of violent conflict: experience in the Democratic Republic of Congo.Incorporating scale dependence in disease burden estimates: the case of human African trypanosomiasis in UgandaThe changing epidemiology of human African trypanosomiasis among patients from nonendemic countries--1902-2012.Sensitivity and Specificity of a Prototype Rapid Diagnostic Test for the Detection of Trypanosoma brucei gambiense Infection: A Multi-centric Prospective StudySocio-economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis.Development of novel drugs for human African trypanosomiasis.Proteomics: a new way to improve human African trypanosomiasis diagnosis?More than meets the eye: understanding Trypanosoma brucei morphology in the tsetse.Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo.Forward motility is essential for trypanosome infection in the tsetse fly.A DBS method for quantitation of the new oral trypanocidal drug fexinidazole and its active metabolites.Trypanosomatid Infections: How Do Parasites and Their Excreted-Secreted Factors Modulate the Inducible Metabolism of l-Arginine in Macrophages?
P2860
Q21144517-02DBB2E8-5C8E-4855-926D-6B4EE71ABB94Q26745974-F95D377D-4C69-45DD-A77F-7A6232D27887Q28474074-8848447A-1D54-4303-97AD-DB6CB474753FQ28533660-EE16E3F6-084E-46E1-9150-3CD8EC23FB46Q29056943-FB0D8907-953F-4744-BD2F-236C56456650Q33828884-A1775EC2-230A-445A-B90D-6134FB8DFC36Q33834072-B4B2C529-AD57-4725-AA4C-4010B13161F0Q33988882-D407B5A7-38C6-45CD-89F8-E082DCBE16D2Q35047661-10F05F27-7EF6-48DF-A242-FC0DD237D5E6Q35097828-DFFB17C3-8B1C-4BAD-B308-EAF07AD48C0FQ35106194-749B4DFF-9886-408A-B119-5C8E8C0F5F6DQ35983488-E261255E-5790-46F6-B8FE-8510E9F65B95Q37811110-BB1F5D9B-0A34-4770-8F08-0CEF82DF8004Q37894699-C83702AF-4E1F-42DE-88E6-8A8915787064Q38115332-D8AE0DE0-8813-4ED7-B1A2-78A92D1FB49DQ38169164-BDAE953C-9AE1-4834-B33F-989825076F9CQ39223286-3264B3F6-F2C0-4AAD-B88C-AF87E6B84743Q45857679-889D7CE8-466A-4D41-9608-745115490B0BQ46268194-57CCDDF1-A490-429D-98B7-7BC049D49F7EQ53685684-6C7FBA3E-B894-4D51-B19E-C1FC8FD49841
P2860
Human African trypanosomiasis in areas without surveillance.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Human African trypanosomiasis in areas without surveillance.
@en
Human African trypanosomiasis in areas without surveillance.
@nl
type
label
Human African trypanosomiasis in areas without surveillance.
@en
Human African trypanosomiasis in areas without surveillance.
@nl
prefLabel
Human African trypanosomiasis in areas without surveillance.
@en
Human African trypanosomiasis in areas without surveillance.
@nl
P2093
P2860
P356
P1476
Human African trypanosomiasis in areas without surveillance.
@en
P2093
Francois Chappuis
Koert Ritmeijer
Laurence Flevaud
Maria Angeles Lima
P2860
P304
P356
10.3201/EID1602.090967
P577
2010-02-01T00:00:00Z